https://www.selleckchem.com/products/xl092.html
nities for targeted therapies that could alter the clinical course of heart failure. The outcomes of immune checkpoint inhibitors in cancer patients with liver metastases are poor, which may be related to a different tumor microenvironment in liver metastases from primary tumors. This study was aimed to analyze PD-L1 expression and the immune microenvironment status in liver metastases and compare the differences of PD-L1 expression between primary tumors and liver metastases of colorectal cancer. 74 cases of pathologically confirmed colo
Like
Comment
Share
